GlassScriptPhysician profile
Brian Charles Erb
NPI 1659469559
$2,349.69
in general payments reported to CMS, 2019-2025
13 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2021: $1,327 · 2022: $116 · 2023: $197 · 2024: $314 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,326.56 | 2021 | |
| Calliditas Therapeutics US INC. | $377.41 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $123.01 | 2024 | |
| Veloxis Pharmaceuticals, INC. | $95.63 | 2022 | |
| Nxstage Medical, INC. | $80.29 | 2024 | |
| Bard Peripheral Vascular, INC. | $72.61 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Vantive US Healthcare LLC | $50.95 | 2025 | Renal - Chronic |
| Akebia Therapeutics INC | $42.07 | 2022-2023 | Auryxia |
| Astrazeneca Pharmaceuticals LP | $33.41 | 2023 | Farxiga |
| Cook Medical LLC | $30.95 | 2019 | |
| Lilly USA, LLC | $29.73 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.87 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Erb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.